P/B
2,7
Cerenome
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
$14.6M
Market Cap • 10/9/2026
1997
(29 years)
Founded
2000
(26 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
3,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,7
EPS
—
Market Cap
Market Cap
14,6M
EV
6,1M
EV/Revenue
1,5
EV/EBITDA
-0,2
EV/EBIT
-0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-256,7%
Total Yield
-256,7%
Payout
0%
Retained Earnings
-531,8M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
297,6%
Capex/Revenue
32,7%
Capex/D&A
302%
Capex/OCF
-6,2%
SBC/OCF
—
% PPE
10,3%
% Goodwill
2,7%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
21,8%
CAGR Net Income 5Y
18,3%
CAGR EPS 5Y
-65%
CAGR OCF 5Y
15,2%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
1,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!